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Objective: To compare lipid-lowering efﬁcacy of adding alirocumab to rosuvastatin versus other treat-
ment strategies (NCT01730053).
Methods: Patients receiving baseline rosuvastatin regimens (10 or 20 mg) were randomized to: add-on
alirocumab 75 mg every-2-weeks (Q2W) (1-mL subcutaneous injection via pre-ﬁlled pen); add-on
ezetimibe 10 mg/day; or double-dose rosuvastatin. Patients had cardiovascular disease (CVD) and low-
density lipoprotein cholesterol (LDLeC) 70 mg/dL (1.8 mmol/L) or CVD risk factors and LDLeC
100 mg/dL (2.6 mmol/L). In the alirocumab group, dose was blindly increased at Week 12 to 150 mg
Q2W (also 1-mL volume) in patients not achieving their LDLeC target. Primary endpoint was percent
change in calculated LDLeC from baseline to 24 weeks (intent-to-treat).
Results: 305 patients were randomized. In the baseline rosuvastatin 10 mg group, signiﬁcantly greater
LDLeC reductions were observed with add-on alirocumab (50.6%) versus ezetimibe (14.4%;
p < 0.0001) and double-dose rosuvastatin (16.3%; p < 0.0001). In the baseline rosuvastatin 20 mg
group, LDLeC reduction with add-on alirocumab was 36.3% compared with 11.0% with ezetimibe
and 15.9% with double-dose rosuvastatin (p ¼ 0.0136 and 0.0453, respectively; pre-speciﬁed threshold
for signiﬁcance p < 0.0125). Overall, ~80% alirocumab patients were maintained on 75 mg Q2W. Of
alirocumab-treated patients, 84.9% and 66.7% in the baseline rosuvastatin 10 and 20 mg groups,
respectively, achieved risk-based LDLeC targets. Treatment-emergent adverse events occurred in 56.3%
of alirocumab patients versus 53.5% ezetimibe and 67.3% double-dose rosuvastatin (pooled data).
Conclusions: The addition of alirocumab to rosuvastatin provided incremental LDLeC lowering versus
adding ezetimibe or doubling the rosuvastatin dose.
© 2015 Regeneron Pharmaceuticals, Inc. Published by Elsevier Ireland Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).t de la Nation, 21000, Dijon,
ier).
blished by Elsevier Ireland Ltd. Th1. Introduction
Among the therapies currently approved for lowering low-
density lipoprotein cholesterol (LDLeC), statins are the most
commonly prescribed and have shown the greatest ability to lower
LDLeC and reduce coronary heart disease (CHD) events [1,2].
Recent studies have also shown that the addition of ezetimibe tois is an open access article under the CC BY-NC-ND license (http://creativecommons.
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risk patients [3]. Further, guidelines recommend higher intensity
lipid-lowering therapy (LLT), primarily with statins, in very high-
risk patient groups [2,4e6]. It should be noted, however, that
some patients are unable to tolerate high-intensity statins [2].
Despite the availability of statins and other LLT, evenwhen they are
used in combination, many high-risk patients do not reach target
LDLeC levels [7].
Alirocumab, a fully human monoclonal antibody to proprotein
convertase subtilisin/kexin type 9 (PCSK9), is currently in devel-
opment for LDLeC-lowering. Phase 2 and 3 studies have shown
that alirocumab signiﬁcantly reduces LDLeC levels by 40e70% as
monotherapy or when added to statins, with or without other LLTs
[8e16]. Adverse events with alirocumab have generally been
comparable to those observed in the control groups; however,
injection-site reactions and pruritus occurred slightly more
frequently in alirocumab-treated patients in the Phase 3 studies
[8e16].
This study compared the lipid-lowering efﬁcacy and safety of
alirocumab, in a head-to-head fashion, with other current options
for patients on rosuvastatin 10 or 20 mg with very-high or high
cardiovascular (CV) risk according to European guidelines [6,7] and
who had LDLeC levels above 70 or 100 mg/dL (1.8 or 2.6 mmol/L),
respectively.
2. Methods
ODYSSEY OPTIONS II was a double-blind, double-dummy, ran-
domized, Phase 3 study, and patients were enrolled in 79 sites in
Australia, Germany, Italy, Spain, the United Kingdom, Mexico, the
United States, and Canada from November 2012 to May 2014
(NCT01730053). The design and rationale for the trial have been
published previously [17]. The protocol was reviewed and approved
by the Institutional Review Board/Ethics Committee at each
participating center and the study was conducted in accordance
with International Conference on Harmonization/Good Clinical
Practice, the Declaration of Helsinki and local regulations. All par-
ticipants provided written informed consent.
2.1. Study participants
The study included adult patients with hypercholesterolemia at
very-high or high CV risk receiving rosuvastatin 10 or 20mg/day for
at least 4 weeks prior to screening. Patients could also be receiving
other LLTs except for ezetimibe; statins other than rosuvastatin
were not allowed. Very-high CV risk patients with a history of CHD,
non-CHD CV disease (CVD), or diabetes mellitus with target organ
damage were included if LDLeC was 70 mg/dL (1.8 mmol/L) at
screening. High-risk CV patients without documented CHD or CVD
but with a 10-year risk of fatal CVD 5% (Systematic Coronary Risk
Evaluation), moderate chronic kidney disease, or diabetes with no
target organ damage, were included if LDLeC was 100 mg/dL
(2.6 mmol/L).
2.2. Study design
Patients entered a 2- to 6-week screening period and were then
randomized according to their baseline rosuvastatin regimen
(10 mg or 20 mg/day) (Supplementary Fig. 1). Patients were ran-
domized in a 1:1:1 ratio to 24 weeks' double-blind treatment with
either (1) add-on therapy with subcutaneous (SC) alirocumab
75 mg every 2 weeks (Q2W), (2) add-on therapy with ezetimibe
10 mg/day, or (3) doubling of the rosuvastatin dose (i.e. 10 mg
doubled to 20 mg/day, or 20 mg doubled to 40 mg/day). Patients
also received SC or oral placebo as appropriate.If Week 8 LDLeC levels were70mg/dL (1.8 mmol/L) in patients
with documented CVD or diabetes mellitus with target organ
damage, or 100 mg/dL (2.6 mmol/L) in all of the other patients,
the alirocumab dose was increased to 150 mg Q2W at Week 12 in a
blinded manner.
2.3. Study assessments and endpoints
Patients returned to the clinic for assessment at Weeks 4, 8, 12,
16, 24 (end of treatment), and Week 32 (end of study follow-up
visit). Adherence to injectable and oral study drug dosing was
documented in a dosing diary, and measured in terms of mean
injection and daily capsule frequency as well as injection and
capsule compliance intervals.
The primary efﬁcacy endpoint was the percent change from
baseline in calculated LDLeC at Week 24, on-treatment or off-
treatment, in the intent-to-treat (ITT) population. The ITT popula-
tion was deﬁned as all randomized patients with a baseline
calculated LDLeC value and post-baseline calculated LDLeC value
during at least one of the planned time points, regardless of the
patient's adherence to study treatment. The primary ITT analysis
compared the efﬁcacy of the alirocumab arm versus each
comparator arm via pairwise comparisons for each baseline entry
rosuvastatin regimen, for a total of four comparisons. In an addi-
tional pre-speciﬁed analysis, pooled data from the alirocumab
groups from the two baseline rosuvastatin dose regimens were
pooled and compared with pooled data from the comparator
groups.
In a pre-speciﬁed hierarchical order [17], key secondary end-
points included the percent change from baseline in calculated
LDLeC on-treatment at Week 24 in the modiﬁed ITT (mITT) pop-
ulation (on-treatment analysis), percent change in LDLeC from
baseline to Week 12 (ITT and on-treatment), the percent change in
other lipid parameters, and the proportion of very-high and high
CV risk patients reaching LDLeC <70 mg/dL (1.8 mmol/L) or
<100 mg/dL (2.6 mmol/L) at Week 24, respectively, in both ITT and
on-treatment analyses. The mITT population was deﬁned as all
randomized and treated patients with a baseline calculated LDLeC
value and with on-treatment calculated LDLeC values during at
least one of the planned post-baseline time points. The on-
treatment window was deﬁned as the period up to 21 days after
last injection/3 days after last capsule (whichever came ﬁrst) at
planned time points from Weeks 4e24.
Safety was evaluated by adverse events (AEs), laboratory tests,
vital signs, physical examination, and electrocardiogram. The
treatment-emergent AE (TEAE) period was deﬁned as the period
between the ﬁrst dose of study drug up to 70 days after last in-
jection. Certain safety events were designated of special interest
based on the alirocumab mode of action, theoretical risks raised in
the literature or potential risks based on any ﬁndings in preclinical
studies.
Anti-drug antibodies (ADAs) to alirocumab were assessed in all
patients. Samples were collected at clinic visits, before adminis-
tration of study drug, and were assayed using a validated immu-
noassay by Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA).
The duration of the ADA response was classiﬁed as: “persistent”, at
least 2 consecutive post-baseline samples with positive ADA
separated by at least a 12-week period; “indeterminate”, ADA
positive response present only at the last sampling point; or
“transient”, any treatment-emergent positive ADA response neither
considered persistent nor indeterminate.
2.4. Statistical analysis
A total sample size of 300 patients (50 in each of the six
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difference in means of at least 20% in any of the 4 pairwise com-
parisons of the primary efﬁcacy endpoint, using a 2-sided t-test
with an adjusted signiﬁcance level of 1.25% for each of the 4 pair-
wise comparisons (i.e. Bonferroni adjustment giving 5% signiﬁ-
cance overall). If any of the 4 pairwise comparisons had p < 0.0125,
it would therefore be declared signiﬁcant. This assumed a standard
deviation of 25% in change from baseline in LDLeC (based on pre-
vious experience with alirocumab) [10]. The multiplicity for testing
key secondary efﬁcacy endpoints was adjusted for by hierarchical
procedure within each of the 4 pairwise comparisons. Inferential
conclusions about successive key secondary parameters for pair-
wise comparisons require statistical signiﬁcance of the primary and
prior key secondary efﬁcacy endpoints within the same pairwise
comparison hierarchy.
To estimate treatment effects at the speciﬁed time points for
primary and key secondary efﬁcacy endpoints that were approxi-
mately normal distributions, a mixed-effect model with a repeated
measures approach was used to account for missing data [18,19].
Least-squares means estimates were calculated, and treatment
differences between patients treated with alirocumab and com-
parators were tested through pairwise comparisons for each entry
statin dose. A sensitivity analysis using a pattern mixture model
was also performed.
For the non-normal lipoprotein (a) (Lp[a]) and triglycerides, a
robust regression model was used. The proportion of patients with
LDLeC <70 mg/dL (1.8 mmol/L) and <100 mg/dL (2.6 mmol/L) was
analyzed using a stratiﬁed exact conditional logistic regression
model. The treatment group was treated as the main effect andTable 1
Baseline characteristics (all randomized patients).
Entry statin 10 mg RSV (n ¼ 145)
ALI þ 10 mg
RSV (n ¼ 49)
EZE þ 10 mg
RSV (n ¼ 48)
RSV
(n ¼
Age, years mean (SD) 62.2 (11.1) 60.4 (10.4) 61.5
Male, n (%) 31 (63.3) 26 (54.2) 33
Race, n (%)
White 45 (91.8) 42 (87.5) 37
Black or African-American 2 (4.1) 6 (12.5) 6
Ethnicity, Hispanic/Latino, n (%) 7 (14.3) 6 (12.5) 6
BMI, kg/m2, mean (SD) 31.8 (7.7) 32.1 (7.3) 32.0
HeFH, n (%) 8 (16.3) 6 (12.5) 4
CHD history, n (%) 23 (46.9) 29 (60.4) 25
CHD risk equivalent, n (%)a 16 (32.7) 12 (25.0) 15
Hypertension, n (%) 36 (73.5) 33 (68.8) 34
Type II diabetes, n (%) 19 (38.8) 23 (47.9) 28
Use of LLT other than statins, n (%) 11 (22.4) 8 (16.7) 11
Baseline lipid parameters, mg/dL, mmol/L or g/L
LDLeC (calculated)
Mean (SD) 107.3 (26.4) 102.4 (41.9) 105.
Mean (SD) 2.780 (0.684) 2.653 (1.085) 2.74
LDLeC (measured)
Mean (SD) 106.0 (29.1) 94.7 (33.6) 100.
Mean (SD) 2.745 (0.753) 2.453 (0.870) 2.59
Non-HDLeC, mean (SD) 138.0 (37.5) 131.7 (48.8) 136.
Mean (SD) 3.575 (0.971) 3.411 (1.263) 3.54
Apo B, mean (SD) 93.4 (22.6) 89.0 (25.9) 92.7
Mean (SD) 0.934 (0.226) 0.890 (0.259) 0.92
Lp(a), median (Q1:Q3) 22.0 (8.0:74.0) 38.5 (14.0:106.0) 26.0
Median (Q1:Q3) 0.22 (0.080:0.740) 0.385 (0.140:1.060) 0.26
Fasting TGs, median (Q1:Q3) 116.0 (86.0:199.0) 127.0 (95.0:163.5) 130.
Median (Q1:Q3) 1.311 (0.972:2.249) 1.435 (1.074:1.848) 1.47
HDL-C, mean (SD) 49.4 (12.7) 51.0 (13.0) 48.5
Mean (SD) 1.281 (0.329) 1.322 (0.336) 1.25
ALI, alirocumab; Apo, apolipoprotein; BMI, body mass index; CHD, coronary heart diseas
familial hypercholesterolemia; LDLeC, low-density lipoprotein cholesterol; LLT, lipid-low
triglycerides.
a CHD risk equivalents were deﬁned as ischemic stroke, peripheral artery disease, modbaseline LDLeC value as a covariate stratiﬁed by randomization
factor in both models. Missing values were handled by the multiple
imputation approach.
The safety analysis included all randomized patients who
received at least one dose or part of a dose of study treatment
(safety population). Safety data are pooled (where appropriate)
across rosuvastatin baseline regimens and are reported as the
pooled alirocumab add-on group, pooled ezetimibe add-on group,
and pooled rosuvastatin group.3. Results
3.1. Patients
Across the two rosuvastatin baseline regimens (10 and 20 mg
respectively), a total of 305 patients were randomized to one of the
six treatment groups (Supplementary Fig. 2). The safety population
included all 305 patients, and the ITT and mITT populations
excluded 7 and 10 patients, respectively, due to missing post-
baseline LDLeC values. Combining both baseline rosuvastatin
groups, 87 (84.5%), 84 (83.2%), and 90 (89.1%) patients randomized
to the alirocumab add-on, ezetimibe add-on, and double-dose
rosuvastatin groups, respectively, completed 24 weeks of the
double-blind treatment period (deﬁned as at least 22 weeks of
treatment and Week 24 visit performed). Baseline patient charac-
teristics were generally similar across treatment groups (Table 1).
Treatment adherence to study drug injections was high in all
treatment groups within the pooled dose regimen, with a mean
overall adherence of 97.5% in the alirocumab add-on group, 98.6% inEntry statin 20 mg RSV (n ¼ 160)
20 mg
48)
ALI þ 20 mg
RSV (n ¼ 54)
EZE þ 20 mg
RSV (n ¼ 53)
RSV 40 mg
(n ¼ 53)
(11.1) 57.9 (8.9) 63.1 (10.2) 60.6 (10.1)
(68.8) 28 (51.9) 31 (58.5) 38 (71.7)
(77.1) 42 (77.8) 46 (86.8) 44 (83.0)
(12.5) 6 (11.1) 2 (3.8) 5 (9.4)
(12.5) 5 (9.3) 7 (13.2) 10 (18.9)
(6.2) 30.2 (6.0) 30.2 (5.4) 31.5 (6.7)
(8.3) 6 (11.1) 8 (15.1) 9 (17.0)
(52.1) 32 (59.3) 32 (60.4) 36 (67.9)
(31.3) 11 (20.4) 11 (20.8) 14 (26.4)
(70.8) 40 (74.1) 36 (67.9) 42 (79.2)
(58.3) 18 (33.3) 21 (39.6) 17 (32.1)
(22.9) 11 (20.4) 13 (24.5) 9 (17.0)
9 (36.0) 118.3 (32.2) 119.0 (48.0) 112.9 (43.3)
3 (0.933) 3.065 (0.834) 3.082 (1.243) 2.924 (1.122)
2 (37.1) 114.1 (30.0) 115.2 (48.4) 108.6 (43.3)
4 (0.960) 2.955 (0.777) 2.984 (1.254) 2.813 (1.120)
9 (41.7) 145.8 (36.6) 149.0 (49.7) 143.6 (44.4)
6 (1.079) 3.777 (0.949) 3.859 (1.288) 3.720 (1.151)
(25.2) 97.8 (20.4) 100.8 (25.9) 96.7 (23.6)
7 (0.252) 0.978 (0.204) 1.008 (0.259) 0.967 (0.236)
(8.0:48.0) 49.5 (16.0:105.0) 35.5 (15.0:76.0) 28.0 (6.0:70.0)
0 (0.080:0.480) 0.495 (0.160:1.050) 0.355 (0.150:0.760) 0.280 (0.060:0.700)
5 (90.5:203.0) 116.0 (91.0:179.0) 143.0 (93.0:192.0) 143.0 (108.0:190.0)
5 (1.023:2.294) 1.311 (1.028:2.023) 1.616 (1.051:2.170) 1.616 (1.220:2.147)
(14.2) 51.8 (11.0) 52.2 (13.7) 46.9 (13.6)
7 (0.369) 1.342 (0.284) 1.352 (0.355) 1.216 (0.353)
e; EZE, ezetimibe; HDL-C, high-density lipoprotein cholesterol; HeFH, heterozygous
ering therapy; Lp(a), lipoprotein(a); RSV, rosuvastatin; SD, standard deviation; TGs,
erate chronic kidney disease, or diabetes (only if two or more risk factors present).
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vastatin group. Of the 92 patients in the pooled alirocumab group
who received at least one injection of study drug, 17 (18.5%) pa-
tients had their dose increased to alirocumab 150 mg Q2WatWeek
12: 7 (15.9%) patients in the baseline rosuvastatin 10 mg regimen
and 10 (20.8%) patients in the baseline rosuvastatin 20mg regimen.
3.2. Efﬁcacy
In the baseline rosuvastatin 10 mg regimen ITT analysis, alir-
ocumab add-on treatment signiﬁcantly reduced LDLeC levels at
Week 24 versus the other comparators (p < 0.0001) (Fig. 1). From
baseline, add-on alirocumab reduced LDLeC by 50.6%, add-on
ezetimibe reduced LDLeC by 14.4%, and double-dose (20 mg)
rosuvastatin reduced LDLeC by 16.3%. LDLeC reductions in the
alirocumab add-on group were observed by Week 4 and were
maintained through Week 24 (Supplementary Fig. 3).
In the baseline rosuvastatin 20 mg regimen ITT analysis, mean
reductions from baseline in LDLeC at Week 24 were greater in the
alirocumab add-on group versus the other comparators (Fig. 1).
LDLeC reductions were 36.3% in the add-on alirocumab group,
compared with 11.0% in the add-on ezetimibe group (p ¼ 0.0136)
and with 15.9% in the double-dose (40 mg) rosuvastatin group
(p ¼ 0.0453). However, the pre-speciﬁed threshold p-value for
these 4-way comparisons was 0.0125, therefore both primary
comparisons failed to reach statistical signiﬁcance and, as a result,
all key secondary efﬁcacy endpoints were not tested for statistical
signiﬁcance with respect to the two comparisons in the baseline
rosuvastatin 20 mg regimen. Investigation of the data suggests a
larger variability in the baseline rosuvastatin 20mg regimen (Fig. 1)
than previously observed. In part, the larger variability can be
attributed to an outlying observation in one patient in the rosu-
vastatin 20 mg þ ezetimibe group, caused by the low, Day 1, pre-
dose calculated LDLeC value of 13 mg/dL (~0.34 mmol/L). Howev-
er, this patient's low calculated LDLeC at baseline had been
conﬁrmed against the measured LDLeC (beta-quantiﬁcation) for
the same blood draw and deemed by the central lipid laboratory to
be correct. The mean LDLeC reductions from baseline over time in
the alirocumab groups compared with the ezetimibe add-on andFig. 1. Percent change in calculated LDLeC from baseline to Week 24 (ITT analysis). EZE,
squares; RSV, rosuvastatin; SE, standard error. p-values achieved statistical signiﬁcance at t
(SE) % difference in calculated LDLeC versus comparator agents at Week 24: *36.1 (6.1); y
model with repeated measures analysis.double-dose rosuvastatin treatment groups are shown in
Supplementary Fig. 3.
Between group differences in LDLeC reductions in the on-
treatment analysis were consistent with the primary analysis
(Supplementary Table 1) as were results with LDLeC measured
using beta quantiﬁcation and pattern mixture model analysis
(Supplementary Tables 2 and 3).
An analysis which pooled data from both the baseline rosu-
vastatin 10 mg and 20 mg regimens conﬁrmed a greater LDLeC-
lowering effect for alirocumab add-on treatment compared with
the double-dose rosuvastatin treatment and ezetimibe add-on
treatment at Week 12 (ITT analysis) and Week 24 (ITT and on-
treatment analyses). In these pooled analyses, measures of vari-
ability were less affected by individual values and the overall
sample numbers were larger. Accordingly, the nominal p-value was
<0.0001 for all comparisons (alirocumab add-on versus ezetimibe
add-on and alirocumab add-on versus double-dose rosuvastatin
treatment) at Week 12 (ITT analysis) and Week 24 (ITT and on-
treatment analyses) (Supplementary Table 4). Of further note, in
the pooled dose regimen in patients who received a dose increase,
the mean percent change from baseline in calculated LDLeC at
Week 12 was 20.3%. When the alirocumab dose was increased
from 75 to 150 mg, there was a further 14% decrease in LDLeC
observed at Week 24 (34.4% from baseline) (Supplementary
Fig. 4).
3.2.1. Proportion of patients achieving LDLeC goals
In the baseline rosuvastatin 10 mg regimen groups, the propor-
tion of patients at very-high and high CV risk who reached a LDLeC
level of <70 mg/dL (1.8 mmol/L) or <100 mg/dL (2.6 mmol/L) at
Week 24, depending on risk status, was signiﬁcantly greater in the
alirocumab add-on group (84.9%) compared with the ezetimibe
add-on group (57.2%; p¼ 0.0007) and the rosuvastatin 20mg group
(45.0%; p < 0.0001) (Fig. 2). The proportion of patients who reached
the more stringent LDLeC level of <70 mg/dL (1.8 mmol/L) at Week
24 was also signiﬁcantly greater in the alirocumab add-on group
(77.8%) compared with the ezetimibe add-on and rosuvastatin
20mg groups (43.1%; p< 0.0001 and 31.3%; p< 0.0001), respectively
(Fig. 2).ezetimibe; ITT, intent-to-treat; LDLeC, low-density lipoprotein cholesterol; LS, least
he 0.0125 level; nominal p-values are provided for descriptive purposes only. LS mean
34.2 (5.9); z25.3 (10.1); x20.3 (10.1). LS means, SE, and p-value taken from mixed-
Fig. 2. Proportion of patients achieving LDLeC goals at Week 24: (a) LDLeC <70 mg/dL (very-high CV risk) or <100 mg/dL (high CV risk); (b) LDLeC <70 mg/dL (regardless of CV
risk). CV, cardiovascular; EZE, ezetimibe; LDLeC, low-density lipoprotein cholesterol; Q2W, every 2 weeks; RSV, rosuvastatin. LDLeC goals: very-high risk, <70 mg/dL (1.8 mmol/L),
high-risk: <100 mgdL (2.6 mmol/L). p-values are for pairwise comparisons between alirocumab and comparator groups within each baseline regimen. Differences were signiﬁcant
for the baseline rosuvastatin 10 mg regimen according to the hierarchical testing procedure, with a signiﬁcance threshold of 0.0125 to account for 4 primary pairwise comparisons.
The primary comparisons for the baseline rosuvastatin 20 mg regimen were signiﬁcant versus the rosuvastatin 40 mg treatment group but not versus add-on ezetimibe and p-
values are shown for descriptive purposes only.
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portion of very-high and high risk patients who reached a LDLeC
level of <70 mg/dL (1.8 mmol/L) or <100 mg/dL (2.6 mmol/L) at
Week 24, depending on risk status, was 66.7% in the alirocumab
add-on group, 52.2% in the ezetimibe add-on group (nominal
p ¼ 0.1177), and 40.1% in the rosuvastatin 40 mg treatment group
(nominal p ¼ 0.0022) (Fig. 2). The proportion of patients who
reached a LDLeC level of <70 mg/dL (1.8 mmol/L) at Week 24 was
60.1% in the alirocumab add-on group, 43.6% in the ezetimibe add-on group (nominal p¼ 0.0657), and 29.9% in the rosuvastatin 40mg
group (nominal p ¼ 0.0006) (Fig. 2).
3.2.2. Other lipid parameters
Signiﬁcant reductions in apolipoprotein (Apo) B, non-high-
density lipoprotein cholesterol (non-HDLeC), and Lp(a) were seen
in the alirocumab add-on group versus other comparators in the
baseline rosuvastatin 10mg regimen (Table 2). The alirocumab add-
on group also produced modest reductions in triglycerides and
Table 2
Percent change from baseline in key secondary lipid endpoints (ITT analysis).
LS mean (SE) change from baseline, % Entry statin RSV 10 mg Entry statin RSV 20 mg
ALI þ RSV 10
mg (n ¼ 48)
EZE þ RSV 10
mg (n ¼ 47)
RSV 20
mg (n ¼ 48)
ALI þ RSV 20
mg (n ¼ 53)
EZE þ RSV 20
mg (n ¼ 50)
RSV 40
mg (n ¼ 52)
Calculated LDLeC Week 12 49.6 (4.1) 17.4 (4.2) 17.1 (4.1) 32.3 (5.2) 19.3 (5.4) 22.1 (5.3)
Difference ALI vs comparator e 32.2 (5.8) 32.5 (5.8) e 12.9 (7.5) 10.2 (7.4)
p-value e <0.0001* <0.0001* e 0.0861 0.1747
Non-HDLeC Week 24 42.7 (3.5) 13.4 (3.7) 11.3 (3.4) 31.4 (5.2) 12.9 (5.2) 11.2 (5.1)
Difference ALI vs comparator e 29.3 (5.1) 31.4 (4.9) e 18.4 (7.3) 20.1 (7.3)
p-value e <0.0001* <0.0001* e 0.0133 0.0063
Apo B Week 24 36.5 (3.1) 9.7 (3.1) 7.3 (3.0) 28.3 (4.3) 11.2 (4.3) 9.8 (4.1)
Difference ALI vs comparator e 26.8 (4.4) 29.2 (4.3) e 17.1 (6.1) 18.5 (6.0)
p-value e <0.0001* <0.0001* e 0.0057 0.0024
Lp(a), Week 24 27.9 (4.1) 4.3 (4.5) 4.0 (4.3) 22.7 (5.1) 5.8 (4.6) 5.2 (4.8)
Difference ALI vs comparator e 23.6 (6.2) 23.9 (5.9) e 16.9 (6.8) 17.5 (7.0)
p-value e 0.0001* <0.0001* e 0.0131 0.0123
Fasting TG Week 24 11.2 (4.6) 8.3 (4.8) 1.8 (4.5) 8.7 (4.5) 11.1 (4.3) 9.9 (4.1)
Difference ALI vs comparator e 2.9 (6.6) 9.3 (6.4) e 2.4 (6.2) 1.2 (6.1)
p-value e 0.6639 0.1454 e 0.7039 0.8459
HDL-C Week 24 9.1 (2.4) 4.0 (2.5) 1.7 (2.4) 7.2 (2.3) 1.8 (2.3) 1.5 (2.3)
Difference ALI vs comparator e 5.1 (3.5) 7.4 (3.4) e 9.0 (3.3) 5.7 (3.3)
p-value e 0.1491 0.0311 e 0.0072 0.0866
ALI, alirocumab; Apo, apolipoprotein; EZE, ezetimibe; HDL-C, high-density lipoprotein cholesterol; ITT, intent-to-treat; LDLeC, low-density lipoprotein cholesterol; Lp(a),
lipoprotein (a); LS, least squares; RSV, rosuvastatin; SD, standard deviation; SE, standard error; TG, triglycerides.
LS means, SE, and p-value taken from a mixed-model with repeated measures analysis with hierarchical procedure to control for type I error except for Lp(a) and TG, which
were analyzed using multiple imputation approach to account for missing values, followed by robust regression model with the endpoint of interest as the response variable
and the treatment group and corresponding baseline values as effects.
p-values are for alirocumab versus comparator.
*p-values with an asterisk were formally tested based on the predeﬁned hierarchical sequence and achieved statistical signiﬁcance at the 0.0125 level; nominal p-values are
provided for descriptive purposes only.
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In the baseline rosuvastatin 20 mg regimen, decreases in Apo B,
non-HDLeC, and Lp(a) were observed in the alirocumab add-on
group when compared with the ezetimibe add-on and rosuvasta-
tin 40 mg groups (Table 2).
3.3. Safety
The summary of safety results are presented by the treatment
groups of pooled rosuvastatin dose regimens in order to maximize
the detection of potential safety signals. For pooled data, 3 treat-
ment groups were formed by combining treatment groups in each
of the baseline rosuvastatin regimens: the add-on alirocumab
treatment group, pooling the alirocumab þ rosuvastatin 10 mg
group and the alirocumabþ rosuvastatin 20 mg group; the double-
dose rosuvastatin treatment group, pooling the placebo-
alirocumab þ rosuvastatin 20 mg group and the placebo-
alirocumab þ rosuvastatin 40 mg group; and the add-on ezetimibe
treatment group, pooling the ezetimibeþ rosuvastatin 10mg group
and the ezetimibe þ rosuvastatin 20 mg group.
The incidence of TEAEs was generally similar across treatment
groups in the pooled dose regimens, with 58 patients (56.3%)
experiencing a TEAE in the alirocumab add-on group, 54 patients
(53.5%) in the ezetimibe add-on group, and 68 patients (67.3%) in
the double-dose rosuvastatin group (Table 3). A total of 22 patients
(7.2%) experienced a serious AE (SAE): 6 patients (5.8%) in the
alirocumab add-on group, 8 patients (7.9%) in the ezetimibe add-on
group, and 8 patients (7.9%) in the double-dose rosuvastatin group.
One patient (0.3%) who was randomized to the
ezetimibe þ rosuvastatin 20 mg group died of a subdural hema-
toma during the course of the study; the death was adjudicated as a
CV death. A total of 18 patients (5.9%) discontinued treatment
prematurely due to a TEAE: 5 (4.9%) in the alirocumab add-on
group, 8 (7.9%) in the ezetimibe add-on group and 5 (5.0%) in the
double-dose rosuvastatin group. Nine patients (8.7%) in thealirocumab add-on group, 2 patients (2.0%) in the ezetimibe add-on
group and 7 patients (6.9%) in the double-dose rosuvastatin group
had a potential general allergic TEAE. Of these, 2 patients (1.9%) in
the alirocumab add-on group experienced a general allergic TEAE
that led to study drug being permanently discontinued. In terms of
safety events of interest, local injection-site reactions, all mild in
intensity, were experienced by 4 patients (3.9%) in the alirocumab
add-on group, 2 patients (2.0%) in the double-dose rosuvastatin
group, and none in the ezetimibe group; none of the local injection-
site reactions led to treatment discontinuation. Neurological TEAEs
of interest were reported in 2 patients (1.9%) in the alirocumab add-
on group, 3 patients (3.0%) in the ezetimibe add-on group, and 2
patients (2.0%) in the double-dose rosuvastatin group. One patient
(1.0%) in each group within the pooled dose regimen experienced a
neurocognitive TEAE. No neurocognitive TEAEs were considered
SAEs and none led to permanent study drug discontinuation. One
patient (1.0%) in each of the ezetimibe add-on and double-dose
rosuvastatin groups experienced a CV TEAE that was conﬁrmed
by adjudication. The CV event in the ezetimibe add-on group
(ezetimibe þ rosuvastatin 20 mg) was adjudicated as non-fatal
myocardial infarction; the CV event in the double-dose rosuvasta-
tin group (rosuvastatin 20 mg) was adjudicated in the category of
fatal and non-fatal ischemic stroke. Creatine kinase more than 3
times the upper limit of normal was observed in 3 patients (3.1%) in
the ezetimibe add-on group, 2 patients (2.0%) in the double-dose
rosuvastatin group, and none in the alirocumab add-on group.
One patient (1.0%) in the alirocumab add-on group had an increase
in alanine aminotransferase (ALT) over 3 times the upper limit of
normal; no patients in any treatment group had both ALT over 3
times the upper limit of normal and total bilirubin over 2 times the
upper limit of normal. Further, no patients in any treatment group
experienced a conﬁrmed hemolytic anemia TEAE or experienced an
ophthalmological TEAE during the study (Table 3). Further details
on AEs are provided in Supplementary Table 5.
Table 3
Safety analysis (safety population pooled across statin entry regimens).
% (n) of patients Pooled ALI 75/150 (n ¼ 103) Pooled EZE (n ¼ 101) Pooled double RSV (n ¼ 101)
Any TEAEs 56.3 (58) 53.5 (54) 67.3 (68)
Treatment-emergent SAEs 5.8 (6) 7.9 (8) 7.9 (8)
TEAE leading to death 0 1.0 (1) 0
TEAEs leading to discontinuation 4.9 (5) 7.9 (8) 5.0 (5)
Most frequently reported TEAEs by preferred term (5% of patients in any group)
Nasopharyngitis 3.9 (4) 5.0 (5) 6.9 (7)
Upper respiratory tract infections 5.8 (6) 4.0 (4) 8.9 (9)
Dizziness 2.9 (3) 2.0 (2) 5.0 (5)
Pain in extremity 1.9 (2) 3.0 (3) 7.9 (8)
Safety events of special interest
Allergic eventsa 8.7 (9) 2.0 (2) 6.9 (7)
Injection-site reactions 3.9 (4) 0 2.0 (2)
Adjudicated CV eventsb 0 1.0 (1) 1.0 (1)
Hemolytic anemia 0 0 0
Neurocognitive disordersc 1.0 (1) 1.0 (1) 1.0 (1)
Neurologic disordersd 1.9 (2) 3.0 (3) 2.0 (2)
Ophthalmologic eventse 0 0 0
Laboratory values
ALT >3  ULN, % (n/N) 1.0 (1/101) 0/99 0/100
Creatine kinase >3  ULN, % (n/N) 0/98 3.1 (3/97) 2 (2/100)
ALI, alirocumab; ALT, alanine aminotransferase; CV, cardiovascular; EZE, ezetimibe; RSV, rosuvastatin; SAE, serious adverse event; TEAE, treatment-emergent adverse event;
ULN, upper limit of normal.
a The selection of preferred terms is based on Standardized MedDRA (Medical Dictionary for Regulatory Activities) Queries: “hypersensitivity” (broad þ narrow) excluding
the following preferred terms: “infusion-site dermatitis”, “infusion-site hypersensitivity”, “infusion-site rash”, “injection-site rash”, “injection-site urticaria”, and “injection-
site vasculitis”.
b Adjudicated CV events include all CV adverse events positively adjudicated. The adjudication categories are the following: CHD death, non-fatal myocardial infarction, fatal
and non-fatal ischemic stroke, unstable angina requiring hospitalization, congestive heart failure requiring hospitalization, and ischemia-driven revascularization procedure
(percutaneous coronary intervention, coronary artery bypass graft).
c The selection of preferred terms is based on a Custom MedDRA Query that was based on the following ﬁve High-Level Group Terms: “deliria (including confusion),”
“cognitive and attention disorders and disturbances,” “dementia and amnestic conditions,” “disturbances in thinking and perception,” and “mental impairment disorders.”
d The selection of preferred terms is based on Standardized MedDRA Queries: “demyelination” (broad þ narrow), “peripheral neuropathy” (broad þ narrow) and “Guillain-
Barre syndrome” (broad þ narrow) excluding the following preferred terms (“acute respiratory distress syndrome”, “asthenia”, “respiratory arrest”, and “respiratory failure”).
e The selection of preferred terms is based on StandardizedMedDRA Queries: “optic nerve disorders” (broadþ narrow), “retinal disorders” (narrow), and “corneal disorders”
(narrow).
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Two patients (2.5%) in the alirocumab add-on group were
negative at baseline in the ADA assay but positive in one or more
post-dose samples. Both patients appeared to demonstrate a
treatment-emergent ADA response, but all samples exhibited low
levels of reactivity in the assay. Of these 2 patients, 1 patient had a
transient response while the other patient had an indeterminate
response. Overall, in these 2 patients who developed ADAs,
immunogenicity was low and ADA assay positivity did not have an
effect on the LDLeC-lowering efﬁcacy of alirocumab during this
study, nor were any particular safety concerns observed.
4. Discussion
Many patients at high or very-high risk for CVD do not achieve
LDLeC treatment goals with existing therapies [20,21]. While sta-
tins are recommended as ﬁrst-line therapy for LDLeC-lowering
[1,2], their use, even when used in combination with other thera-
pies, does not always enable patients to reach their individual
LDLeC target levels [7]. This study compared adding alirocumab
therapy versus adding ezetimibe or doubling the rosuvastatin dose
in patients at high or very-high CV risk.
In the baseline rosuvastatin 10mg regimen, treatmentwith add-
on alirocumab therapy signiﬁcantly reduced calculated LDLeC
levels at Week 24 when compared with doubling the dose of
rosuvastatin regimen or ezetimibe add-on therapy. In the rosu-
vastatin 10 mg baseline regimen group, alirocumab add-on therapy
also signiﬁcantly improved key secondary endpoints, such as levels
of Apo B, non-HDLeC, and Lp(a), as well as the proportion of pa-
tients achieving pre-speciﬁed LDLeC levels.Consistent with the results in the baseline rosuvastatin 10 mg
treatment regimen, greater reductions in calculated LDLeC levels
were observed in the group receiving add-on alirocumab to rosu-
vastatin 20 mg when compared with doubling the rosuvastatin
dose or an ezetimibe add-on treatment regimen. However, these
differences did not reach the p-value threshold of 0.0125 for these
multiple comparisons. The failure to reach statistical signiﬁcance
could be explained, in part, by the large standard error in the LDLeC
values in the baseline rosuvastatin 20 mg group compared with the
baseline rosuvastatin 10 mg group (7.1 versus 4.2, respectively),
which was greater than estimated in the original power
calculations.
Further, it should be noted that the ﬁndings in both baseline
rosuvastatin treatment regimens are inconsistent with LDLeC-
lowering effects seen in the literature. In the add-on ezetimibe
groups, LDLeC reductions of 14.4% and 11.0% were found in the
baseline rosuvastatin 10 mg and 20 mg regimens, respectively,
compared with an average 20% reduction seen in published studies
[22]. In addition, a greater than expected LDLeC level reductionwas
observed with doubling of the statin dose, 16.3% in the baseline
rosuvastatin 10 mg regimen and 15.9% in the baseline rosuvastatin
20 mg regimen, which is more than the expected reduction of a
further 6% as seen in other studies in which the statin dose is
doubled [23]. These observed differences may be due to the small
number of patients studied and a high inter-individual variability.
Measures of variabilitywere less affected by individual values in the
pooled analysis; the nominal p-value for the change in LDLeC was
<0.0001 for all comparisons between treatment groups at Week 12
(ITT analysis) and Week 24 (ITT and on-treatment analyses).
In this study, alirocumab demonstrated consistent LDLeC re-
ductions in patients receiving stable rosuvastatin therapy, as well as
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studies in patients with non-familial hypercholesterolemia on
various, stable doses of statins, or those with heterozygous familial
hypercholesterolemia on stable doses of statin with or without
ezetimibe, alirocumab demonstrated robust, consistent, and sig-
niﬁcant reductions in LDLeC levels by 40%e70%, as well as re-
ductions in Apo B, non-HDLeC, and Lp(a) [8e16]. Reports of other
PCSK9 inhibitors have also shown reductions in LDLeC and other
lipoproteins across a range of patient populations and background
therapies [24e27]. In addition, these data conﬁrm earlier reports
that substantial reductions in Lp(a) are observed in patients
receiving alirocumab.
A ﬂexible alirocumab dosing regimen, which allowed for the
alirocumab dose to be increased only when patients did not reach
their individual LDLeC goals (depending on their CV risk) by a pre-
speciﬁed time point (Week 8), was also evaluated in this study. All
patients receiving alirocumab began the study on a regimen of
75 mg Q2Wandmore than 80% of patients were maintained on the
75 mg Q2W dose; in the pooled alirocumab treatment groups, 17
patients (18.5%) had their dose increased to alirocumab 150 mg
Q2W at Week 12 in a blinded manner.
Patients who remained on 75 mg Q2W maintained the reduc-
tion in calculated LDLeC levels observed fromWeek 12 toWeek 24,
while patients who had their dose increased to 150 mg at theWeek
12 visit showed a further reduction in LDLeC levels from Week 12
to Week 24. In the pooled dose regimen in patients who received a
dose increase to 150 mg Q2W, the mean percent change from
baseline in calculated LDLeC at Week 12 was20.3% with a further
14% reduction observed at Week 24.
Overall, the addition of alirocumab produced greater LDLeC-
lowering than its comparators over the entire 24-week study
period, demonstrating durability of effect over this time period.
Alirocumab was well tolerated and the numbers of patients
reporting TEAEs were similar across treatment groups. No safety
signals were detected for alirocumab add-on therapy when
compared with doubling the statin dose or ezetimibe add-on
therapy. The overall rate of AEs of special interest, which were
chosen based on the alirocumab mode of action, theoretical risks
raised from literature, or potential risks based on any ﬁndings in
preclinical studies, was low. There were few reports of allergic re-
actions or local injection-site reactions, although more frequent in
the alirocumab group than in the comparator groups. In addition,
the rates of ALT and creatine kinase over 3 times the upper limit of
normal were low and no patients in any treatment group had ALT
over 3 times the upper limit of normal and total bilirubin over 2
times the upper limit of normal. Antibodies to alirocumab were
observed in 2 patients receiving alirocumab but did not impact
overall safety, nor was there an effect on efﬁcacy. Further, this study
reﬂects the safety proﬁle demonstrated by alirocumab across Phase
2 and 3 studies, in which a total of 5234 patients with hypercho-
lesterolemia were included in the double-blind safety pool; 3340
patients received alirocumab for an overall exposure of 3451
patient-years. In the Phase 2 and 3 pooled safety analysis, the rates
of TEAEs, treatment-emergent SAEs, and TEAEs leading to perma-
nent treatment discontinuation were similar between the alir-
ocumab and control groups. Among the common TEAEs, injection-
site reactions (7.3% versus 5.2%) and pruritus (1.1% versus 0.4%)
were identiﬁed as more common in patients receiving alirocumab
than control. In addition, the rates of neurologic events, neuro-
cognitive events, hepatic disorders, and clinically meaningful
changes in glycemic control were generally similar to placebo and
ezetimibe in the pooled data [28].
As many high-risk patients do not achieve LDLeC goals on
current therapies, there is an unmet need for new therapeutic
options to reduce risk in such patients. In patients withhypercholesterolemia at high or very-high CV risk, alirocumab
provided clinically important and incremental reductions in LDLeC
compared with the currently available options, namely the addition
of ezetimibe or doubling the statin dose. Both alirocumab 75 mg
and 150 mg are well tolerated, allowing a treat-to-target approach
in patients not at their LDLeC goal. Further studies, including the
ODYSSEY Outcomes trial (NCT01663402), will provide additional
efﬁcacy and safety data on alirocumab.
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